Check it out: our co-founder and chief scientific officer Ethan Weiss joined Brad Loncar and BiotechTV to chat all things Marea, the risk of remnant cholesterol and how we are combining human genetics and adipose biology to develop novel therapies for patients at risk for heart attacks even after controlling classical risk factors such as #obesity and elevated LDL #cholesterol. Listen below.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After exiting stealth mode with $190M today, Marea Therapeutics co-founder Ethan Weiss describes ANGPTL4 as a cardiometabolic target and more. He describes the difference between ANGPTL4 and ANGPLT3, the rationale for lowering remnant cholesterol, Marea's plans beyond this target, and his upcoming Timmerman Traverse hike for charity. Full video: https://lnkd.in/gQ9u7aQj BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent